Modulation of FOXP3 Expression and Regulatory T-Cell Activity by Gum Rosin-Modified Ointment: A Multi-Phase Preclinical and Clinical Study for Psoriasis Treatment
ISEF · 2026 Translational Medical Science
Overview
Psoriasis silently torments 125 million people worldwide, yet current therapies such as corticosteroids and biologics thin the skin, suppress the immune system, and lose efficacy over time, while neither addresses the disease's immunological root. The 2025 Nobel Prize in Physiology or Medicine validated FOXP3+ Regulatory T-cells (Tregs) as master regulator of immune tolerance. A pathway that is critically deficient in psoriasis, exposing a precise therapeutic target for psoriasis. This study engineered Rosiderm: a topical ointment of gum rosin, a natural pine resin rich in abietic and dehydroabietic acid, targeting both immune dysregulation and epidermal hyperproliferation simultaneously. Across 3 rigorously controlled studies, safety, efficacy and stability of Rosiderm were validated. First, in-vivo study was done with a 36-rabbit imiquimod-induced psoriasis model, Rosiderm achieved 88% severity reduction versus 48% for the betamethasone-salicylic acid standard, a 184% faster recovery (p<0.0001; Cohen's d=0.84). Immunohistochemistry confirmed marked FOXP3+ Treg upregulation. Second, Phase I dose-escalation human trial (n=40, 8/group) demonstrated dose-proportional systemic absorption across all cohorts (R²=0.978), with Cmax ranges from 0.22 ± 0.05 to 0.63 ± 0.18 ng/mL across the 5–20% concentrations. No severe adverse events recorded. Third, phase II double-blinded human trial (n=125, 25/group) showed Rosiderm achieving 90% severity reduction, with PASI-75 response in 21 of 25 patients, significantly outperforming the standard betamethasone (p<0.001). The formulation physical stability was confirmed across 8 months. Together, these findings establish Rosiderm as a safe, affordable and efficacious alternative to existing therapies for millions of patients globally.
Competition history
- ISEF 2026
Resources
Related projects
ISEF · 2025
Comparative Evaluation of Gum Rosin-Based Ointment and Betamethasone-Salicylic Acid in Treating Imiquimod-Induced Psoriasis in Rabbits
ISEF · 2025
Unlocking CRAC Channel Modulation: Plant Metabolite-Derived ORAI1 Inhibitors Targeting E106 for Rheumatoid Arthritis Treatment Through Combined AI-Derived Virtual Screening Approaches
ISEF · 2017
Harnessing Anti-Inflammatory and Immunomodulatory Potentials from Nature for Cancer Therapy
ISEF · 2025
Unveiling Synergistic Anti-Inflammatory Effects of Neem Leaf Bioactives: A Low-Cost, Eco-Friendly Breakthrough for Sustainable Disease Treatment
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair